Randomized, Double-Blind, Multicenter,Placebo-Controlled, Dose Ranging, Efficacy and Safety Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout

Trial Profile

Randomized, Double-Blind, Multicenter,Placebo-Controlled, Dose Ranging, Efficacy and Safety Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2013

At a glance

  • Drugs RDEA 806 (Primary)
  • Indications Gout
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 May 2012 Planned number of patients changed from 30 to 60 and additional trial locations (Spain, Belgium) added as reported by European Clinical Trials Database.
    • 09 Oct 2009 Planned end date changed from 1 Apr 2009 to 1 Aug 2009 as reported by ClinicalTrials.gov.
    • 21 Apr 2009 Status changed from recruiting to completed; results reported in an Ardea Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top